Massmutual Trust Co. FSB ADV Acquires 576 Shares of Boston Scientific Co. (NYSE:BSX)

Massmutual Trust Co. FSB ADV boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 16.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,985 shares of the medical equipment provider’s stock after acquiring an additional 576 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Boston Scientific were worth $273,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bruce G. Allen Investments LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth $28,000. Frazier Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $32,000. Sachetta LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $32,000. Jones Financial Companies Lllp raised its position in shares of Boston Scientific by 53.0% during the fourth quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 193 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in shares of Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39. Following the transaction, the executive vice president now owns 45,628 shares of the company’s stock, valued at approximately $3,437,157.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,627 shares of company stock valued at $5,937,353. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.9 %

Shares of NYSE:BSX opened at $76.98 on Friday. The business’s 50 day moving average is $73.71 and its 200 day moving average is $66.59. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $77.64. The stock has a market cap of $112.94 billion, a price-to-earnings ratio of 64.69, a PEG ratio of 2.63 and a beta of 0.81. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. The firm had revenue of $3.86 billion for the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Argus upped their price target on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. TD Cowen lifted their price objective on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Raymond James boosted their price objective on Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research note on Thursday, April 25th. Finally, Wells Fargo & Company raised their target price on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $76.70.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.